Q1 Earnings Estimate for Genmab A/S Issued By HC Wainwright

Genmab A/S (NASDAQ:GMAB) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Genmab A/S in a research report issued to clients and investors on Thursday, January 23rd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of $0.18 for the quarter. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share. HC Wainwright also issued estimates for Genmab A/S’s Q2 2025 earnings at $0.39 EPS, Q3 2025 earnings at $0.43 EPS, Q4 2025 earnings at $0.49 EPS and FY2025 earnings at $1.50 EPS.

A number of other research analysts also recently issued reports on the stock. Redburn Atlantic started coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating on the stock. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Price Performance

Shares of GMAB stock opened at $21.29 on Friday. The firm has a fifty day moving average of $21.07 and a two-hundred day moving average of $23.98. Genmab A/S has a 1-year low of $19.85 and a 1-year high of $31.88. The firm has a market cap of $14.09 billion, a P/E ratio of 20.67, a P/E/G ratio of 0.57 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The firm had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period in the previous year, the business posted $0.47 earnings per share.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. increased its position in shares of Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after acquiring an additional 827 shares in the last quarter. R Squared Ltd purchased a new position in shares of Genmab A/S in the fourth quarter worth approximately $93,000. Blue Trust Inc. increased its position in shares of Genmab A/S by 33.4% in the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock worth $120,000 after acquiring an additional 1,442 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Genmab A/S by 82.7% during the fourth quarter. SG Americas Securities LLC now owns 26,396 shares of the company’s stock worth $551,000 after purchasing an additional 11,949 shares during the period. Finally, Crossmark Global Holdings Inc. boosted its holdings in shares of Genmab A/S by 8.8% during the fourth quarter. Crossmark Global Holdings Inc. now owns 41,622 shares of the company’s stock worth $868,000 after purchasing an additional 3,377 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.